Gene Therapy on Trial

Abstract
A flurry of reports and congressional hearings, sparked by the death of a volunteer in a study at the University of Pennsylvania in Philadelphia last fall, are due in the next few weeks. The Penn episode points up a central problem: The field still lacks an ideal vector. Many clinicians fear that support for gene therapy will buckle under the onslaught.

This publication has 0 references indexed in Scilit: